MEDISPA.PRO
Ministry of Health code: A11.12.003 Axis M3 · Mitochondrial health and energy metabolism CEBM: Level B (Infusion therapy (IV therapy))

Targeted metabolic infusion of magnesium and coenzymes (Magne+ CoQ10)

Targeted Magnesium & CoQ10 Metabolic Infusion

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
60 min
Turnover: ~75 min
Recommended course
10 sessions
2–3 times a week (5–8 infusions)
Throughput capacity
6 pts
per 8-hour shift
Median rate
—
— – —
Course cost
—
at market median
Publication volume
Level B
7 publ. in PubMed

Clinical profile

Intravenous magnesium (often together with B vitamins) as part of drips. There is evidence for specific medical conditions, acute migraine attacks and asthma exacerbations; there are no clinical studies of intravenous magnesium for "anti-stress", fatigue or general wellness.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Mechanism of action

  • Intravenous magnesium reduces an acute migraine attack as early as 15–45 minutes after the start of the infusion. [1]
  • In asthma exacerbation, intravenous magnesium sulphate acts as a bronchodilator in addition to standard therapy. [4]

Where studies show an effect

  • Acute migraine attack: intravenous magnesium reduces pain at 15–45 minutes, 2 and 24 hours; oral magnesium reduces attack frequency and intensity. [1]
  • Asthma exacerbation in children: fewer hospital admissions and less need for non-invasive ventilation when added to standard treatment. [2, 3]

Open questions and study limitations

  • In sickle cell disease, neither intravenous nor oral magnesium reduced pain crises (Cochrane). [6]
  • Evidence in childhood asthma is of low certainty; most comparisons are based on 1–3 studies. [3, 5]
  • A Cochrane review of magnesium for migraine prevention is only planned (2025 protocol). [7]

Safety

  • Adverse effects of intravenous administration in children with asthma are rare. [2]

Protocol in studies

  • In migraine studies the effect was assessed at 15–45 minutes, 120 minutes and 24 hours after a single infusion. [1]
Contraindications. Contraindications (including renal failure, conduction disorders) are determined by the physician according to the drug instructions; they are not listed in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
B.Braun Perfusor Space infusion pump

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
B.Braun Perfusor Space infusion pump
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.1 120.0 m² · Class B

Treatment room for intravenous infusions / treatment room / laser blood irradiation / ozone therapy room / blood UV irradiation (10 individual cubicles)

General therapeutic interventions and high-tech therapy · Equipment: 11 538 900 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) —
Market median —
75th percentile (P75) —

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Market prices for this procedure are not yet available in industry facilities' price lists, so no benchmark is published.

Evidence base

Meta-analyses confirm the benefit of intravenous magnesium in acute migraine and asthma exacerbation (low to moderate certainty); there are no data for wellness drips.

Publication level B · Some data
  1. 1.
    Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials.
    Pain Physician, 2016 · Meta-analysis of RCTs · PMID 26752497
    Intravenous magnesium reduces an acute migraine attack; oral magnesium reduces attack frequency and intensity.
  2. 2.
    Intravenous magnesium sulfate for asthma exacerbations in children: Systematic review with meta-analysis.
    Paediatr Respir Rev, 2024 · Systematic review and meta-analysis · PMID 38395640
    Asthma exacerbation in children: fewer hospital admissions, better peak expiratory flow; side effects are rare.
  3. 3.
    Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials.
    Arch Dis Child, 2025 · Systematic review and meta-analysis · PMID 40562459
    Low certainty: fewer hospital admissions and less non-invasive ventilation; other outcomes did not differ.
  4. 4.
    Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis.
    Pediatr Pulmonol, 2025 · Network meta-analysis · PMID 40637351
    Among intravenous bronchodilators for severe asthma in children, magnesium ranked first.
  5. 5.
    Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.
    Cochrane Database Syst Rev, 2020 · Overview of Cochrane reviews · PMID 32767571
    Comparisons are based on a small number of small studies; the authors do not yet make firm recommendations.
  6. 6.
    Magnesium for treating sickle cell disease.
    Cochrane Database Syst Rev, 2017 · Cochrane systematic review · PMID 28409830
    Sickle cell disease: magnesium did not reduce pain crises or length of hospital stay.
  7. 7.
    Magnesium supplementation for migraine prophylaxis.
    Cochrane Database Syst Rev, 2025 · Cochrane review protocol · PMID 41216917
    An assessment of magnesium for migraine prevention in children and adults is planned.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.